Putting patients first is what we do. It’s what we should do. And, we don’t expect a special award for doing our job. Still, we can’t help but brag a little -- the Patient First award we received from Corcept Therapeutics made our day!
CuraScript Specialty Pharmacy
Specialty patients often face complex and costly treatments for their therapies. Nonadherence among these patients can lead to expensive and dangerous adverse health effects. Research shows that keeping one organ transplant patient adherent to anti-rejection therapy can prevent more than $19,190 in wasteful medical costs per year.
The World Orphan Drug Congress being held this week presents a unique opportunity for manufacturers, advocacy groups, and patient access providers to meet and discuss how we can all work together to take really good care of small, special patient populations.
One interesting discussion has been about whether small or large providers can best serve the needs of orphan drug manufacturers and their patients.
For those of us connected with manufacturing or managing orphan drugs, it's easy to obsess over the numbers: there are 7,000 designated rare diseases, but fewer than 400 approved orphan drug therapies; more than 30 million Americans have been diagnosed with a rare disease, yet only one-third of those are receiving treatment.